Abstracts tagged "Health care cost and rheumatoid arthritis (RA)"

Abstract Number: 287 • 2018 ACR/ARHP Annual Meeting
Comparison of Real-World Costs between Patients with Rheumatoid Arthritis Treated with Subcutaneously-Administered Biologics Previously Treated with Another Biologic
Jennie H. Best¹, Paul Juneau² and Amanda Kong², ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To compare real-world healthcare costs between patients with rheumatoid arthritis (RA) who were treated with subcutaneously (SC) administered biologics after previously using at least…
Abstract Number: 2507 • 2018 ACR/ARHP Annual Meeting
Healthcare Resource Utilization in Patients with Secondary Sjögren’s Syndrome Associated with RA Compared with Patients with RA in an Insured Population
Evo Alemao¹, Aarti Rao², Chidananda Samal² and Robert Wong¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is a rheumatic disease that may coexist with RA. Joint disease is more severe in patients (pts) with RA with…
Abstract Number: 2999 • 2018 ACR/ARHP Annual Meeting
Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?
Aniket Kawatkar¹, J An², TC Cheetham², Kiran Gupta³, Alexander Marshall⁴, Eric Haupt¹, Gary Okano³ and Tammy Curtice⁵, ¹Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Western University of Health Sciences, Pomona, CA, ³HEOR, Bristol-Myers Squibb, Princeton, NJ, ⁴HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid Arthritis (RA) patients who are anti-citrullinated peptide antibody (ACPA) positive are prone to more severe structural damage, radiographic progression and inferior response to…
Abstract Number: 413 • 2017 ACR/ARHP Annual Meeting
Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
J An¹, Z Bider², J Kang¹, E Alemao³, SE Connolly³ and TC Cheetham¹, ¹Western University of Health Sciences, Pomona, CA, ²Southern California Permanente Medical Group, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibody positivity has been suggested as a strong predictor of joint erosion as well as a potential biomarker for guiding…
Abstract Number: 1033 • 2017 ACR/ARHP Annual Meeting
Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
ML Paudel¹, JP Swindle¹, J McPheeters¹, R Szymialis² and K Price², ¹Optum, Inc., Eden Prairie, MN, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: RA is often treated with a biologic DMARD (bDMARD), such as abatacept (ABA) or a TNF inhibitor (TNFi). Real-world data on how economic outcomes…
Abstract Number: 2834 • 2017 ACR/ARHP Annual Meeting
Healthcare Cost Drivers in Rheumatoid Arthritis
Nina Mars¹, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³University of Helsinki, Helsinki, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify…
Abstract Number: 2303 • 2016 ACR/ARHP Annual Meeting
Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011
Sharan K. Rai^1,2, J. Antonio Avina-Zubieta^2,3, Natalie McCormick^2,4, Mary A. De Vera^2,5, Diane Lacaille^2,6, Eric C. Sayre² and Hyon K. Choi^7,8, ¹Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Gout and rheumatoid arthritis (RA) are the two most common forms of inflammatory arthritis worldwide. As hospitalizations for both conditions lead to substantial health…
Abstract Number: 137 • 2015 ACR/ARHP Annual Meeting
Willingness to Pay for Highly Effective Drug Treatments in Brazilian Rheumatoid Arthritis Patients
Cleandro Albuquerque¹, Pedro Haddad², Vander Fernandes³, Claudia Marques⁴, Sonia Fialho⁵, Adriana Kakehasi⁶, Fabio Jennings⁷, Claiton Brenol⁸, Lícia M. H. Mota^9,10, Geraldo Castelar-Pinheiro^2,11, Angela Duarte¹², Iara Giroto¹³, Maria Raquel C. Pinto¹⁴, Mariana Toni¹⁵, Mirhelen Mendes Abreu¹⁶ and Marcos B. Ferraz¹⁷, ¹Rheumatology, Hospital Universitário de Brasília - UnB, Brasília, Brazil, ²Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ³Universidade de Cuiabá, Cuiaba MT, Brazil, ⁴Disciplina de Reumatologia, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife - PE, Brazil, ⁵Rodovia Virgílio Várzea 1510 B, Universidade Federal de Santa Catarina, Florianópolis, Brazil, ⁶Rua Astolfo Vieira de Resende, Faculdade de Medicina - UFMG, Belo Horizonte, Brazil, ⁷Disciplina de reumatologia, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁸Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁹Rheumatology, University Hospital, Faculty of Medicine, University of Brasília, Brasília/DF, Brazil, ¹⁰Hospital Universitário de Brasília - UnB, Brasília, Brazil, ¹¹Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ¹²Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ¹³Universidade de Cuiabá, Cuiabá, Brazil, ¹⁴Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹⁵Faculdade de Medicina - UFRGS, Porto Alegre, Brazil, ¹⁶Disciplina de Reumatologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁷Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Willingness to pay (WTP) is a technique used for valuing health benefits and individual preferences. Brazil’s national public health system (Sistema Único de Saúde)…
Abstract Number: 145 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis
Zheng-Yi Zhou¹, Jenny Griffith², Arijit Ganguli², Ella Xiaoyan Du¹ and Keith Betts¹, ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Real world studies comparing the healthcare utilization of anti-TNFs vs. non-TNFs as the next alternative after the failure of the first anti-TNF are scarce.…
Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Douglas C. Wolf¹, Martha Skup², Hongbo Yang³, Elizabeth Faust³, Jenny Griffith², Jingdong Chao² and Mark Lebwohl⁴, ¹Atlanta Gastroenterology Associates, Atlanta, GA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Mount Sinai Medical Center, New York, NY
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
Abstract Number: 1290 • 2015 ACR/ARHP Annual Meeting
Burden of Rheumatoid Arthritis in the US Elderly Population: Comorbidities, Healthcare Resource Utilization, and Cost
Chieh-I Chen¹, Li Wang², Wenhui Wei³, Huseyin Yuce⁴ and Kristine Phillips⁵, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Director, Analytic Research, STATinMED Research, Plano, TX, ³Sanofi-Aventis, Bridgewater, NJ, ⁴New York City College of Technology (CUNY), New York, NJ, ⁵Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease resulting in significant healthcare resource utilization (HRCU) and cost. Data on elderly RA patients are generally…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].